Biovica records consecutive quarterly IVD test sales growth of 40-50%, with good prospects ahead. The IVD growth is high, but Biovica probably needs to extend and improve this momentum to reach breakeven by 2025. The Pharma RUO-related sales are also growing in the number of projects, prospects, and sales, considering that two RUO deliveries were delayed until August (outside of Biovica’s Q1). The financial pressure has eased after the recent direct share issue, but the operational pressure is on to reach a quarterly sales level of some SEK 35m by the end of 2025.